Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 5—May 2018
Synopsis

Antimicrobial Resistance in Invasive Bacterial Infections in Hospitalized Children, Cambodia, 2007–2016

Andrew Fox-LewisComments to Author , Junko Takata, Thyl Miliya, Yoel Lubell, Sona Soeng, Poda Sar, Kolthida Rith, Gregor McKellar, Vanaporn Wuthiekanun, Erin McGonagle, Nicole Stoesser, Catrin E. Moore, Christopher M. Parry, Claudia Turner, Nicholas P.J. Day, Ben S. Cooper, and Paul Turner
Author affiliations: University of Oxford, Oxford, UK (A. Fox-Lewis, J. Takata, Y. Lubell, N. Stoesser, C.E. Moore, C. Turner, N.P.J. Day, B.S. Cooper, P. Turner); Angkor Hospital for Children, Siem Reap, Cambodia (A. Fox-Lewis, T. Miliya, S. Soeng, P. Sar, K. Rith, G. McKellar, C. Turner, P. Turner); Cambodia-Oxford Medical Research Unit, Siem Reap (A. Fox-Lewis, T. Miliya, S. Soeng, P. Sar, K. Rith, C. Turner, P. Turner); Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand (Y. Lubell, V. Wuthiekanun, C.E. Moore, N.P.J. Day, B.S. Cooper); University of Colorado, Aurora, Colorado, USA (E. McGonagle); Liverpool School of Tropical Medicine, Liverpool, UK (C.M. Parry); Nagasaki University, Nagasaki, Japan (C.M. Parry)

Main Article

Table 2

Resistance proportions by year of isolation for the 253 non-Global Antimicrobial Resistance Surveillance System pathogens isolated from children at Angkor Hospital for Children, Siem Reap, Cambodia, 2007–2016*

Pathogen, resistance type No. isolates resistant/no. tested (%) Year of isolation
2007–2008 2009–2010 2011–2012 2013–2014 2015–2016
Burkholderia pseudomallei 66 6 10 13 22 15
CAZ 0/66 0/6 0/10 0/13 0/22 0/15
TMP/SXT
 0/61
 0/2
 0/10
 0/12
 0/22
 0/15
Haemophilus influenzae 57 15 15 9 12 6
AMP 30/56 (53.6) 5/14 (35.7) 10/15 (66.7) 7/9 (77.8) 8/12 (66.7) 0/6
CRO 3/57 (5.3) 1/15 (6.7) 1/15 (6.7) 0/9 1/12 (8.3) 0/6
Multidrug
 13/35 (37.1)
 0/0
 5/10 (50.0)
 5/7 (71.4)
 3/12 (25.0)
 0/6
Enterobacter cloacae 42 2 6 8 17 9
AMP–GEN 19/42 (45.2) 1/2 (50.0) 5/6 (83.3) 5/8 (62.5) 6/17 (35.3) 2/9 (22.2)
3GC 34/42 (81.0) 1/2 (50.0) 5/6 (83.3) 7/8 (87.5) 14/17 (82.4) 7/9 (77.8)
Carbapenem 3/41 (7.3) 0/1 0/6 0/8 2/17 (11.8) 1/9 (11.1)
Multidrug
 18/37 (48.6)
 1/1 (100)
 2/2 (100)
 5/8 (62.5)
 7/17 (41.2)
 3/9 (33.3)
Group A Streptococcus 38 2 6 6 13 11
MAC/LIN
 6/37 (16.2)
 0/2
 1/5 (20.0)
 0/6
 2/13 (15.4)
 3/11 (27.3)
Pseudomonas aeruginosa 37 7 6 7 9 8
CAZ 4/34 (11.8) 0/4 1/6 (16.7) 1/7 (14.3) 2/9 (22.2) 0/8
Carbapenem 2/30 (6.7) 0/1 0/5 1/7 (14.3) 0/9 1/8 (12.5)
Multidrug
 0/29
 0/0
 0/5
 0/7
 0/9
 0/8
Neisseria meningitidis 13 6 3 0 2 2
CRO 1/13 (7.7) 0/6 1/3 (33.3) 0/2 0/2

*Resistance proportions have been reported as number of resistant isolates out of number of isolates tested. Blank cell indicates that no organisms were tested during that period and, thus, the proportion of resistant organisms is unknown. 3GC, third-generation cephalosporin; AMP–GEN, resistance to both ampicillin and gentamicin; CAZ, ceftazidime; CRO, ceftriaxone; MAC/LIN, resistance to macrolides and/or lincosamides; TMP/SXT, trimethoprim/sulfamethoxazole.

Main Article

Page created: April 17, 2018
Page updated: April 17, 2018
Page reviewed: April 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external